Dr. Stuart Williams
and Board Director
Leonhardt’s Launchpads, BioLeonhardt, VascuStim (formerly MyoStim Peripheral)
Background & Experience
Dr. Stuart Williams received his Ph.D. in Cell Biology from the University of Delaware
Postdoctoral training in Pathology at the Yale School of Medicine.
During the period 1980 to 1990 he held a faculty appointment at Jefferson Medical College where he was Director of Research in the Department of Surgery.
In 1990 Dr. Williams joined the faculty at the University of Arizona and founded the University of Arizona Biomedical Engineering Program creating a research and educational link between the Medical School and College
of Engineering. He held faculty positions jointly in Biomedical Engineering, Surgery, Physiology and Materials Science and Engineering.
In 2007 Dr. Williams was selected as the Scientific Director of the newly established Cardiovascular Innovation Institute, a partnership between Jewish Hospital and the University of Louisville in Louisville Kentucky.
Established the Bioficial Organs Program to create human tissues and organs for clinical therapeutics and in vitro drug testing using a patient’s own cells. Central to this effort is the use of 3D bioprinting technologies.
Dr. Williams’ research interests have focused on medical devices and regenerative medicine. He developed and patented the first methods to use fat-derived stem and regenerative cells for therapeutic use.
Dr. Williams has authored over 400 scientific publications including scientific papers, abstracts, book chapters and editorials.
His entrepreneurial spirit has resulted in 22 issued US patents with numerous patents pending.
He has founded several biotechnology companies; maintained active managerial positions and has been an active consultant to the medical device, regenerative medicine and pharmaceutical community.
He is a Fellow of the American Heart Association and a Fellow of the American Institute of Medical and Biological Engineering.
“I have been working with the Leonhardt team since the mid 1990’s when we began cell seeding
stent grafts. We have come a long way since then and have learned how to support organ regeneration with not only stem cells but also growth factors, nutrient hydrogels, scaffoldings, matrixes, exosomes, micro RNAs, 3D printing and bioelectric stimulation. It is a delight to see all of this coming together now into a comprehensive therapeutic option.”